Biotricity Inc. has secured 14 new patents for its remote patient monitoring technology, significantly expanding its intellectual property portfolio to 15 total patents, with 14 more pending. The healthcare technology company’s latest innovations focus on a versatile multi-biometric device platform that can function as both a patch and a watch.
The newly patented technology enables a single monitoring device to transition between different form factors, allowing medical providers to adapt the solution based on specific patient needs and clinical requirements. The core components can be inserted into either a patch configuration or transferred to a watch format, enhancing patient compliance and expanding clinical applications.
“At Biotricity, we believe that the future of patient care lies in the ability to monitor and manage individuals from the comfort of their home,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our solutions deliver actionable data to healthcare providers, facilitating quicker intervention to improve patient outcomes while driving revenue through insurance reimbursement.”
A key innovation of the platform is its ability to conduct multiple diagnostic studies simultaneously. For instance, patients requiring both cardiac and sleep studies can now undergo these assessments concurrently using a single device, potentially reducing diagnostic delays and accelerating treatment initiation.
The company’s expanded intellectual property strategy encompasses not only patents but also trade secrets, FDA clearances, and trademarks. Each technological development is strategically aligned with insurance reimbursement requirements and focused on improving clinical outcomes.
The company anticipates securing additional patents throughout 2025 and 2026, further strengthening its position in the remote patient monitoring sector.
Sources: GlobeNewswire, BioSpace
—
March 12, 2025 – by Ali Nassar-Smith
